Document:

Exhibit 10.3

 

SEVERANCE AND CHANGE IN CONTROL AGREEMENT

 

This Severance and
Change in Control Agreement (the “Agreement”) is made and entered into by and between [Executive Name]
(“Executive”) and SOC Telemed, Inc., a Delaware corporation (the “Company”),
effective as of [Date] (the “Effective Date”).

 

RECITALS

 

1. 
The Compensation Committee (the “Committee”) of the Board of Directors of the Company (the “Board”)
recognizes that it is possible that the Company could terminate Executive’s employment with the Company and from time to
time the Company may consider the possibility of an acquisition by another company or other change in control transaction. The
Committee also recognizes that such considerations can be a distraction to Executive and can cause Executive to consider alternative
employment opportunities. The Committee has determined that it is in the best interests of the Company and its stockholders to
assure that the Company will have the continued dedication and objectivity of Executive, notwithstanding the possibility, threat
or occurrence of such a termination of employment or the occurrence of a Change in Control (as defined herein) of the Company.

 

2. 
The Committee believes that it is in the best interests of the Company and its stockholders to provide Executive with an
incentive to continue Executive’s employment with the Company and to motivate Executive to maximize the value of the Company
for the benefit of its stockholders.

 

3. 
The Committee believes that it is imperative to provide Executive with certain severance benefits upon Executive’s
termination of employment and with certain additional benefits following a Change in Control. These benefits will provide Executive
with enhanced financial security and incentive and encouragement to remain with the Company notwithstanding the possibility of
a Change in Control.

 

4. 
The Company and Executive previously entered into an employment agreement dated [Date] (the “Employment Agreement”),
which provided for certain payments and/or benefits upon Executive’s termination of employment.

 

5. 
The Company and Executive wish to restate the terms of Executive’s severance and benefits (whether or not in connection
with a Change in Control) and replace any and all such provisions providing for severance and/or change in control payments and/or
benefits in the Employment Agreement, as set forth below. All other terms and conditions of the Employment Agreement will remain
in full force and effect.

 

6. 
Certain capitalized terms used in the Agreement are defined in Section 5 below.

 

    	 

    	

    

 

AGREEMENT

 

NOW, THEREFORE, in
consideration of the mutual covenants contained herein, the parties hereto agree as follows:

 

1. 
Term of Agreement. This Agreement shall have an initial term effective as of the Effective Date and continuing for
a three (3)-year period (the “Initial Term”), with such term to automatically continue following the
Initial Term for additional one (1)-year periods in accordance with the terms of this Agreement unless either party notifies the
other party in writing of its intention not to renew this Agreement at least 60 days prior to the expiration of the Initial Term
or any applicable extension period hereunder; provided, however, that following a separation pursuant to which payments or benefits
are payable to Executive pursuant to this Agreement, this Agreement will not terminate until all of such payments and benefits
have been satisfied.

 

2. 
Employment. The Company and Executive acknowledge that Executive’s employment is and will continue to be at-will,
as defined under applicable law. If Executive’s employment terminates for any reason, including (without limitation) any
termination of employment not set forth in Section 3, Executive will not be entitled to any payments, benefits, damages, awards
or compensation other than the payment of accrued but unpaid wages, as required by law, and any unreimbursed reimbursable expenses
or pursuant to written agreements with the Company, including equity award agreements.

 

3. 
Termination Benefits.

 

(a) 
Termination without Cause and not in Connection with a Change in Control. If other than during the one (1)-month
period immediately prior to (and in connection with) a Change in Control or the twelve (12)-month period immediately following
a Change in Control, the Company (or any parent, subsidiary or successor of the Company) terminates Executive’s employment
with the Company other than for Cause or Executive becoming Disabled or Executive’s death, then, subject to Section 4, Executive
will be entitled to the following payments and benefits.

 

(i) 
Accrued Compensation. The Company will pay Executive all Accrued Benefits.

 

(ii) 
Severance.

 

(1)
 Executive will receive continuing payments of severance pay, paid in accordance with the Company’s regular payroll
procedures, at a rate equal to Executive’s Base Salary as then in effect for period of six (6) months following the date
of termination (or, if such separation occurs during the one year period commencing on the closing date of the Transaction and
lasting until the first anniversary thereof, then for period of twelve (12) months following the date of termination) and, for
the avoidance of doubt, the payments will be less all required tax withholdings and other applicable deductions, and will be paid
in accordance with the Company’s regular payroll procedures commencing on the Company’s next regularly scheduled payroll
date following the Release Deadline (as defined in Section 4(a)), provided that the first payment shall include any amounts that
would have been paid to Executive if payment had commenced on the date of Executive’s separation from service;

 

    	-2-

    	

    

 

(2) 
Executive will receive a lump sum severance payment equal to the cash incentive compensation bonus (the “Cash
Bonus”) that Executive would have been entitled to receive in respect of the fiscal year in which Executive’s
termination of employment occurs, had Executive continued in employment until the end of such fiscal year, determined based on
actual performance for such year relative to the performance goals applicable to Executive and pro-rated to the number of days
in such fiscal year prior to Executive’s termination of employment and paid at the time comparable bonuses are payable to
other service providers; and

 

(3)
 If Executive elects continuation coverage pursuant to the Consolidated Omnibus Budget Reconciliation Act of 1985, as amended
(“COBRA”) for Executive and Executive’s eligible dependents, within the time period prescribed
pursuant to COBRA, Executive will be eligible for continued coverage under the medical plans of the Company, through reimbursement
or direct remittance of COBRA premiums, in the Company’s sole discretion, at the Company’s sole expense (at the coverage
levels in effect immediately prior to Executive’s termination or resignation) until the earliest of (I) the end of the period
during which Executive is receiving continuing payments of Base Salary under sub-clause (1) of this Section 3(a)(ii), (II) the
maximum period of continuation coverage required under COBRA, or (III) the date upon which Executive and/or Executive’s eligible
dependents become covered under similar plans. COBRA reimbursements, if applicable, will be made by the Company to Executive consistent
with the Company’s normal expense reimbursement policy and will be taxable to the extent required to avoid adverse consequences
to Executive or the Company under either Code Section 105(h) or the Patient Protection and Affordable Care Act of 2010.

 

(b) 
Termination without Cause or Resignation for Good Reason in Connection with a Change in Control. If during the one
(1)-month period immediately prior to (and in connection with) a Change in Control or during the twelve (12)-month period immediately
following a Change in Control (x) the Company terminates Executive’s employment with the Company for a reason other than
Cause or Executive becoming Disabled or Executive’s death, or (y) Executive resigns from such employment for Good Reason,
then, subject to Section 4, Executive will be entitled to the following in lieu of the benefits described in Section 3(a) above:

 

(i) 
Accrued Compensation. The Company will pay Executive all Accrued Benefits.

 

(ii) 
Severance.

 

(1) 
Executive will receive a lump sum severance payment equal to twelve (12) months’ of Executive’s Base Salary
as in effect immediately prior to the date of Executive’s termination of employment (but without taking into account any
reduction in Base Salary that gives rise to a termination for Good Reason), less all required tax withholdings and other applicable
deductions, which will be paid no later than the Release Deadline;

 

    	-3-

    	

    

 

(2) 
If Executive elects continuation coverage pursuant to the COBRA for Executive and Executive’s eligible dependents,
within the time period prescribed pursuant to COBRA, Executive will be eligible for continued coverage under the medical plans
of the Company, through reimbursement or direct remittance of COBRA premiums, in the Company’s sole discretion, at the Company’s
sole expense (at the coverage levels in effect immediately prior to Executive’s termination or resignation) until the earliest
of (I) the end of the period referenced in sub-clause (1) of this Section 3(b)(ii), (II) the maximum period of continuation coverage
required under COBRA, or (III) the date upon which Executive and/or Executive’s eligible dependents become covered under
similar plans. COBRA reimbursements, if applicable, will be made by the Company to Executive consistent with the Company’s
normal expense reimbursement policy and will be taxable to the extent required to avoid adverse consequences to Executive or the
Company under either Code Section 105(h) or the Patient Protection and Affordable Care Act of 2010;

 

(3) 
Executive will receive a lump sum severance payment equal to Executive’s Cash Bonus (calculated based on deemed achievement
of the Performance Goals applicable thereto at target levels), less all required tax withholdings and other applicable deductions,
which will be paid no later than the Release Deadline;

 

(4) 
All of the then unvested shares subject to all time-based stock options and other time-based equity-based awards held by
Executive will immediately vest and, if applicable, become exercisable upon the date of such termination, which shall otherwise
remain subject to their terms; and

 

(5) 
With respect to any unvested shares subject to an equity award held by Executive that is subject to performance-based vesting,
the treatment with respect to each such equity award will be subject to, and governed by, the provisions set forth in the award
agreement evidencing each such equity award.

 

(c) 
Disability; Death; Voluntary Resignation; Termination for Cause. If Executive’s employment with the Company
is terminated due to (i) Executive becoming Disabled or Executive’s death, (ii) Executive’s voluntary resignation (other
than for Good Reason) or (iii) the Company’s termination of Executive’s employment with the Company for Cause, then
Executive (or Executive’s estate, as the case may be) will receive the Accrued Benefits, but will not be entitled to any
other compensation or benefits from the Company except to the extent required by law (for example, COBRA); provided, however, that
if Executive’s employment is terminated due to Executive becoming Disabled or Executive’s death, then (A) Executive
(or Executive’s estate) will also receive a lump sum severance payment equal to Executive’s Cash Bonus (calculated
based on deemed achievement of the Performance Goals applicable thereto at target levels), pro-rated to the number of days in such
fiscal year prior to Executive’s termination of employment and less all required tax withholdings and other applicable deductions;
and (B) any stock options that are vested as of such separation date shall remain exercisable until the earliest of (x) the one
year anniversary of such separation date, (y) the options’ expiration date; or (z) as otherwise provided pursuant to the
equity plan under which such options were issued. All payments set forth in this Section 3(c) shall in all cases be paid within
thirty (30) days of Executive’s termination of employment (or such earlier date as required by applicable law).

 

    	-4-

    	

    

 

(d) 
Timing of Payments. Subject to any specific timing provisions in Section 3(a) through 3(c), as applicable, or the
provisions of Section 4, payment of the severance and benefits hereunder shall be made or commence to be made as soon as practicable
following Executive’s termination of employment.

 

(e) 
Exclusive Remedy. In the event of a termination of Executive’s employment with the Company (or any parent,
subsidiary or successor of the Company), the provisions of this Section 3 are intended to be and are exclusive and in lieu of any
other rights or remedies to which Executive may otherwise be entitled, whether at law, tort or contract, in equity, or under this
Agreement (other than the payment of accrued but unpaid wages, as required by law, and any unreimbursed reimbursable expenses).
Executive will be entitled to no other severance, benefits, compensation or other payments or rights upon a termination of employment,
including, without limitation, any severance payments and/or benefits provided in this Agreement, other than those benefits expressly
set forth in Section 3 or pursuant to written equity award agreements with the Company.

 

(f)  
No Duty to Mitigate. Executive will not be required to mitigate the amount of any payment contemplated by this Agreement,
nor will any earnings that Executive may receive from any other source reduce any such payment.

 

4. 
Conditions to Receipt of Severance.

 

(a) 
Release of Claims Agreement. The receipt of any severance payments or benefits pursuant to this Agreement is subject
to Executive signing and not revoking a separation agreement and release of claims in a form attached to this Agreement as Attachment
A (the “Release”), which must become effective no later than the sixtieth (60th) day following Executive’s
termination of employment (the “Release Deadline”), and if not, Executive will forfeit any right to severance
payments or benefits under this Agreement. To become effective, the Release must be executed by Executive and any revocation periods
(as required by statute, regulation, or otherwise) must have expired without Executive having revoked the Release. In addition,
in no event will severance payments or benefits be paid or provided until the Release actually becomes effective. If the termination
of employment occurs at a time during the calendar year where the Release Deadline could occur in the calendar year following the
calendar year in which Executive’s termination of employment occurs, then any severance payments or benefits under this Agreement
that would be considered Deferred Payments (as defined in Section 4(c)(i)) will be paid on the first payroll date to occur during
the calendar year following the calendar year in which such termination occurs, or such later time as required by (i) the payment
schedule applicable to each payment or benefit as set forth in Section 3, (ii) the date the Release becomes effective, or (iii)
Section 4(c)(ii); provided that the first payment shall include all amounts that would have been paid to Executive if payment had
commenced on the date of Executive’s termination of employment.

 

(b) 
Restrictive Covenants. The receipt of any termination benefits pursuant to Section 3 will be subject to Executive
not having breached any material provisions of the Confidentiality Agreement (as defined in Section 9 below). In the event Executive
breaches the material provisions of the Confidentiality Agreement, as reasonably determined by the Board, all continuing payments
and benefits to which Executive may otherwise be entitled pursuant to Section 3 will immediately cease (other than the Accrued
Benefits).

 

    	-5-

    	

    

 

(c) 
Section 409A.

 

(i) 
Notwithstanding anything to the contrary in this Agreement, no severance pay or benefits to be paid or provided to Executive,
if any, pursuant to this Agreement that, when considered together with any other severance payments or separation benefits, are
considered deferred compensation not exempt under Section 409A (together, the “Deferred Payments”) will
be paid or otherwise provided until Executive has a “separation from service” within the meaning of Section 409A. And
for purposes of this Agreement, any reference to “termination of employment,” “termination” or any similar
term shall be construed to mean a “separation from service” within the meaning of Section 409A. Similarly, no severance
payable to Executive, if any, pursuant to this Agreement that otherwise would be exempt from Section 409A pursuant to Treasury
Regulation Section 1.409A-1(b)(9) will be payable until Executive has a “separation from service” within the meaning
of Section 409A.

 

(ii) 
Notwithstanding anything to the contrary in this Agreement, if Executive is a “specified employee”
within the meaning of Section 409A at the time of Executive’s termination of employment (other than due to death), then the
Deferred Payments, if any, that are payable within the first six (6) months following Executive’s separation from service,
will become payable on the first payroll date that occurs on or after the date six (6) months and one (1) day following the date
of Executive’s separation from service. All subsequent Deferred Payments, if any, will be payable in accordance with the
payment schedule applicable to each payment or benefit. Notwithstanding anything herein to the contrary, if Executive dies following
Executive’s separation from service, but prior to the six (6) month anniversary of the separation from service, then any
payments delayed in accordance with this paragraph will be payable in a lump sum as soon as administratively practicable after
the date of Executive’s death and all other Deferred Payments will be payable in accordance with the payment schedule applicable
to each payment or benefit. Each payment, installment and benefit payable under this Agreement is intended to constitute a separate
payment for purposes of Section 1.409A-2(b)(2) of the Treasury Regulations.

 

(iii) 
Without limitation, any amount paid under this Agreement that satisfies the requirements of the “short-term deferral”
rule set forth in Section 1.409A-1(b)(4) of the Treasury Regulations is not intended to constitute Deferred Payments for purposes
of clause (i) above.

 

(iv) 
Without limitation, any amount paid under this Agreement that qualifies as a payment made as a result of an involuntary
separation from service pursuant to Section 1.409A-1(b)(9)(iii) of the Treasury Regulations that does not exceed the Section 409A
Limit is not intended to constitute Deferred Payments for purposes of clause (i) above. Any payment intended to qualify under this
exemption must be made within the allowable time period specified in Section 1.409A-1(b)(9)(iii) of the Treasury Regulations.

 

(v) 
To the extent that reimbursements or in-kind benefits under this Agreement constitute non-exempt “nonqualified deferred
compensation” for purposes of Section 409A, (1) all reimbursements hereunder shall be made on or prior to the last day of
the calendar year following the calendar year in which the expense was incurred by Executive, (2) any right to reimbursement or
in-kind benefits shall not be subject to liquidation or exchange for another benefit, and (3) the amount of expenses eligible for
reimbursement or in-kind benefits provided in any calendar year shall not in any way affect the expenses eligible for reimbursement
or in-kind benefits to be provided, in any other calendar year.

 

    	-6-

    	

    

 

(vi) 
The payments and benefits provided under Sections 3(a) and Section 3(b) are intended to be exempt from or comply with the
requirements of Section 409A so that none of the severance payments and benefits to be provided hereunder will be subject to the
additional tax imposed under Section 409A, and any ambiguities or ambiguous terms herein will be interpreted to be exempt or so
comply. The Company and Executive agree to work together in good faith to consider amendments to this Agreement and to take such
reasonable actions that are necessary, appropriate or desirable to avoid imposition of any additional tax or income recognition
prior to actual payment to Executive under Section 409A.

 

5.   Definition of Terms. The following terms referred to in this Agreement will have the following meanings:

 

(a) 
Cause. “Cause” means Executive’s:

 

(i) 
willful failure to reasonably and substantially perform Executive’s duties (other than as a result of physical or
mental illness or injury);

 

(ii) 
willful misconduct, intentional misrepresentation or gross negligence which causes injury (or, in the case of willful misconduct,
significant injury) to the Company or any of its affiliates (whether financially, reputationally or otherwise);

 

(iii) 
commission of an act of fraud, embezzlement, misappropriation or a breach by Executive of Executive’s fiduciary duty
or duty of loyalty to the Company or its affiliates;

 

(iv) 
indictment, receipt of a charge or conviction for (or plea of guilty or nolo contendere with respect to) any felony or any
crime involving dishonesty or moral turpitude;

 

(v) 
unlawful use (including being under the influence) or possession of illegal drugs on the Company’s premises;

 

(vi) 
breach by Executive of the material terms of any agreement with the Company or any affiliate or any material Company policies
(including without limitation any improper disclosure of confidential data and breach of any policy related to sexual harassment,
assault or fraternization); or

 

(vii) 
failure of Executive to cooperate with a bona fide internal investigation or an investigation by regulatory or law enforcement
authorities, after being instructed by the Company to cooperate, or the willful destruction or failure to preserve documents or
other materials known to be relevant to such investigation or the inducement of others to fail to cooperate or to produce documents
or other materials in connection with such investigation.

 

    	-7-

    	

    

 

Notwithstanding the
foregoing, the Company may not terminate Executive’s employment for Cause under clauses (i), (ii) or (vi) of this definition
unless (A) the Company or the Board has provided notice to Executive setting forth in reasonable detail the specific conduct
purporting to constitute Cause within ninety (90) days of the date the Company or the Board first becomes aware of its existence,
(B) Executive has failed to cure such conduct (if capable of cure) within seven (7) days following the date of receipt of
such notice, and (C) the Board or the Company has terminated Executive’s employment within thirty (30) days following
such failure to cure. Notwithstanding the foregoing, if following the termination of Executive’s services, it is determined
that Executive’s services could have been terminated for Cause, as such term is defined above, Executive’s services
shall, at the election of the Board, be deemed to have been terminated for Cause retroactively to the date the events giving rise
to Cause occurred.

 

(b) 
Change in Control. “Change in Control” has the meaning ascribed to such term in the Company’s
2020 Equity Incentive Plan, as may be amended and restated from time to time; provided, however, that the consummation of the Transaction
shall not be deemed to constitute a Change in Control for purposes of this Agreement.

 

(c) 
Code. “Code” means the Internal Revenue Code of 1986, as amended.

 

(d) 
Disability. “Disability” or “Disabled” means that Executive is unable to engage in any substantial
gainful activity by reason of any medically determinable physical or mental impairment which can be expected to result in death
or which has lasted, or can be expected to last, for a continuous period of not less than one (1) year.

 

(e) 
Good Reason. “Good Reason” means the occurrence of any of the following events without
the Executive’s prior written consent: (i) any reduction in Base Salary, except for across-the-board salary reductions
similarly affecting all or substantially all senior management employees of the Company; (ii) any material diminution in
the Executive’s duties, title or responsibilities (provided, however, that a reduction in title solely by virtue of the Company
being acquired and made part of a larger entity, as, for example, when the CEO of the Company remains as such following a change
of control but is not made the CEO of the acquiring corporation) will not constitute Good Reason); (iii) a relocation of
the Executive’s principal place of employment (excluding any remote work arrangement) such that Executive’s normal
daily one-way commute is increased by more than 35 miles as compared to Executive’s principal place of employment (excluding
any remote work arrangement) as of the Effective Date; or (iv) a breach by the Company of any material obligation under
any written agreement between the Executive and the Company or the failure of any successor to the Company to assume this Agreement.
Notwithstanding the foregoing, Executive may not terminate Executive’s employment for Good Reason unless (A) the Executive
has provided notice to the Board setting forth in reasonable detail the specific conduct of the Company or the Board purporting
to constitute Good Reason within ninety (90) days of the date the Executive first becomes aware of its existence, (B) the
Board has failed to cure such conduct within seven (7) days following the date of receipt of such notice, and (C) the Executive
has terminated Executive’s employment within thirty (30) days following such failure to cure.

 

    	-8-

    	

    

 

(f)  
Governmental Authority. “Governmental Authority” means any federal, state, municipal, foreign
or other government, governmental department, commission, board, bureau, agency or instrumentality, or any private or public court
or tribunal.

 

(g) 
Person. “Person” shall be construed in the broadest sense and means and includes any natural
person, a partnership, a corporation, an association, a joint stock company, a limited liability company, a trust, a joint venture,
an unincorporated organization and other entity or Governmental Authority.

 

(h) 
Section 409A. “Section 409A” means Section 409A of the Code, and the final regulations
and any guidance promulgated thereunder or any state law equivalent.

 

(i) 
Section 409A Limit. “Section 409A Limit” shall mean two (2) times the lesser of: (i) Executive’s
annualized compensation based upon the annual rate of pay paid to Executive during Executive’s taxable year preceding Executive’s
taxable year of Executive’s separation from service as determined under Treasury Regulation Section 1.409A-1(b)(9)(iii)(A)(1)
and any Internal Revenue Service guidance issued with respect thereto; or (ii) the maximum amount that may be taken into account
under a qualified plan pursuant to Section 401(a)(17) of the Code for the year in which Executive’s separation from service
occurred.

 

(j) 
Transaction. “Transaction” shall mean, collectively, the transactions contemplated by that
certain Agreement and Plan of Merger by and among Healthcare Merger Corp., Sabre Merger Sub I, Inc., Sabre Merger Sub II, LLC,
and the Company, dated as of July 29, 2020.

 

6.   Golden Parachute.

 

(a) 
Anything in this Agreement to the contrary notwithstanding, if any payment or benefit Executive would receive from the Company
or otherwise (“Payment”) would (i) constitute a “parachute payment” within the meaning
of Section 280G of the Code; and (ii) but for this sentence, be subject to the excise tax imposed by Section 4999 of
the Code (the “Excise Tax”), then such Payment shall be equal to the Reduced Amount. The “Reduced
Amount” shall be either (x) the largest portion of the Payment that would result in no portion of the
Payment being subject to the Excise Tax; or (y) the largest portion, up to and including the total, of the Payment, whichever
amount, after taking into account all applicable federal, state and local employment taxes, income taxes, and the Excise Tax (all
computed at the highest applicable marginal rate), results in Executive’s receipt, on an after-tax basis, of the greater
amount of the Payment. Any reduction made pursuant to this Section 6(a) shall be made in accordance with the following order of
priority: (i) stock options whose exercise price exceeds the fair market value of the optioned stock (“Underwater Options”)
(ii) Full Credit Payments (as defined below) that are payable in cash, (iii) non-cash Full Credit Payments that are taxable, (iv)
non-cash Full Credit Payments that are not taxable, (v) Partial Credit Payments (as defined below) and (vi) non-cash employee welfare
benefits. In each case, reductions shall be made in reverse chronological order such that the payment or benefit owed on the latest
date following the occurrence of the event triggering the excise tax will be the first payment or benefit to be reduced (with reductions
made pro-rata in the event payments or benefits are owed at the same time). “Full Credit Payment” means
a payment, distribution or benefit, whether paid or payable or distributed or distributable pursuant to the terms of this Agreement
or otherwise, that if reduced in value by one dollar reduces the amount of the parachute payment (as defined in Section 280G of
the Code) by one dollar, determined as if such payment, distribution or benefit had been paid or distributed on the date of the
event triggering the excise tax. “Partial Credit Payment” means any payment, distribution or benefit
that is not a Full Credit Payment.

 

    	-9-

    	

    

 

(b) 
A nationally recognized certified public accounting firm selected by the Company (the “Accounting Firm”)
shall perform the foregoing calculations related to the Excise Tax. If a reduction is required pursuant to Section 6(a), the Accounting
Firm shall administer the ordering of the reduction as set forth in Section 6(a). The Company shall bear all expenses with respect
to the determinations by such accounting firm required to be made hereunder.

 

(c) 
The Accounting Firm engaged to make the determinations hereunder shall provide its calculations, together with detailed
supporting documentation, to Executive and the Company within fifteen (15) calendar days after the date on which Executive’s
right to a Payment is triggered. Any good faith determinations of the Accounting Firm made hereunder shall be final, binding, and
conclusive upon Executive and the Company.

 

(d) 
Notwithstanding anything to the contrary in Section 9(a), if any Payment that would be otherwise reduced pursuant to Section
9(a) would not be so reduced if the stockholder approval requirements of Section 280G(b)(5) of the Code are capable of being satisfied,
the Company will use its reasonable best efforts to cause such payments to be timely submitted for such approval in accordance
with such requirements.

 

7.  Arbitration.

 

(a) 
Arbitration. In consideration of Executive’s Employment with the Company, its promise to arbitrate all employment-related
disputes, and Executive’s receipt of the compensation, pay raises and other benefits paid to Executive by the Company, at
present and in the future, Executive agrees that any and all controversies, claims, or disputes with anyone (including the Company
and any employee, officer, director, shareholder or benefit plan of the Company in their capacity as such or otherwise) arising
out of, relating to, or resulting from Executive’s Employment with the Company or termination thereof, including any breach
of this Agreement, will be subject to binding arbitration pursuant to Virginia law. The Federal Arbitration Act shall also apply
with full force and effect.

 

(b) 
Dispute Resolution. Disputes that Executive agrees to arbitrate, and thereby agrees to waive any right to a jury
trial, include any statutory claims under local, state, or federal law, including, but not limited to, claims under Title VII of
the Civil Rights Act of 1964, the Americans with Disabilities Act of 1990, the Age Discrimination in Employment Act of 1967, the
Older Workers Benefit Protection Act, the Sarbanes Oxley Act, the Worker Adjustment and Retraining Notification Act, the Virginia
Human Rights Act, the Virginia Values Act, the Virginia Labor Code, claims of harassment, discrimination, and wrongful termination,
and any statutory or common law claims. Executive further understands that this agreement to arbitrate also applies to any disputes
that the Company may have with Executive.

 

    	-10-

    	

    

 

(c) 
Procedure. Executive agrees that any arbitration will be administered by Judicial Arbitration & Mediation Services,
Inc. (“JAMS”), pursuant to its Employment Arbitration Rules & Procedures (the “JAMS Rules”).
The arbitrator shall have the power to decide any motions brought by any party to the arbitration, including motions for summary
judgment and/or adjudication, motions to dismiss and demurrers, and motions for class certification, prior to any arbitration hearing.
The arbitrator shall have the power to award any remedies available under applicable law, and the arbitrator shall award attorneys’
fees and costs to the prevailing party, except as prohibited by law. The Company will pay for any administrative or hearing fees
charged by the administrator or JAMS, and all arbitrator’s fees, except that Executive shall pay any filing fees associated
with any arbitration that Executive initiates, but only so much of the filing fee as Executive would have instead paid had Executive
filed a complaint in a court of law. Executive agrees that the arbitrator shall administer and conduct any arbitration in accordance
with Virginia law, and that the arbitrator shall apply substantive and procedural Virginia law to any dispute or claim, without
reference to the rules of conflict of law. To the extent that the JAMS Rules conflict with Virginia law, Virginia law shall take
precedence. The decision of the arbitrator shall be in writing. Any arbitration under this Agreement shall be conducted in Virginia.

 

(d) 
Remedy. Arbitration shall be the sole, exclusive, and final remedy for any dispute between Executive and the Company.
Accordingly, except as provided by this Agreement, neither Executive nor the Company will be permitted to pursue court action
regarding claims that are subject to arbitration. Notwithstanding, the arbitrator will not have the authority to disregard
or refuse to enforce any lawful Company policy, and the arbitrator will not order or require the Company to adopt a policy not
otherwise required by law that the Company has not adopted.

 

(e) 
Administrative Relief. Executive is not prohibited from pursuing an administrative claim with a local, state, or
federal administrative body or government agency that is authorized to enforce or administer laws related to employment, including,
but not limited to, the Department of Fair Employment and Housing, the Equal Employment Opportunity Commission, the National Labor
Relations Board, or the Workers’ Compensation Board. However, Executive may not pursue court action regarding any such claim,
except as permitted by law.

 

(f)  
Voluntary Nature of Agreement. Executive acknowledges and agrees that Executive is executing this Agreement voluntarily
and without any duress or undue influence by the Company or anyone else. Executive further acknowledges and agrees that Executive
has carefully read this Agreement and that Executive has asked any questions needed for Executive to understand the terms, consequences
and binding effect of this Agreement and fully understands it, including that EXECUTIVE IS WAIVING EXECUTIVE’S RIGHT
TO A JURY TRIAL.

 

(g) 
Independent Advice. Executive acknowledges that Executive has been advised to obtain independent advice and legal
counsel to advise Executive concerning this Agreement, and that Executive has either done so or has knowingly waived that opportunity
of Executive’s own free choice. Neither the Company nor any attorneys for the Company have advised Executive concerning this
Agreement, and Executive is relying solely upon the advice of Executive’s own independent counsel (if any); nor has the Company
or any attorneys for the Company coerced, used undue influence, or otherwise induced Executive to enter into this Agreement.

 

    	-11-

    	

    

 

8.   Successors.

 

(a) 
Company’s Successors. This Agreement shall be binding upon any successor (whether direct or indirect and whether
by purchase, lease, merger, consolidation, liquidation or otherwise) to all or substantially all of the Company’s business
and/or assets. For all purposes under this Agreement, the term “Company” shall include any successor
to the Company’s business or assets that become bound by this Agreement or any affiliate of any such successor that employs
Executive.

 

(b) 
Executive’s Successors. This Agreement and all of Executive’s rights hereunder shall inure to the benefit
of, and be enforceable by, Executive’s personal or legal representatives, executors, administrators, successors, heirs, distributees,
devisees and legatees.

 

(c) 
Headings. All captions and section headings used in this Agreement are for convenient reference only and do not form
a part of this Agreement.

 

9. 
Confidential Information. Executive agrees to continue to comply with and be bound by the Employee Nondisclosure,
Non-Solicitation, Confidentiality and Developments Agreement (the “Confidentiality Agreement”) entered
into by and between Executive and the Company, dated as of the date hereof.

 

10.   Notice.

 

(a) 
General. Notices and all other communications contemplated by this Agreement shall be in writing and shall be deemed
to have been duly given when personally delivered or when mailed by U.S. registered or certified mail, return receipt requested
and postage prepaid. In Executive’s case, mailed notices shall be addressed to Executive at the home address that Executive
most recently communicated to the Company in writing. In the case of the Company, mailed notices shall be addressed to its corporate
headquarters, and all notices shall be directed to the attention of its Secretary.

 

(b) 
Notice of Termination. Any termination by the Company for Cause or by Executive for Good Reason will be communicated
by a notice of termination to the other party hereto given in accordance with Section 10(a) of this Agreement. Such notice will
indicate the specific termination provision in this Agreement relied upon, will set forth in reasonable detail the facts and circumstances
claimed to provide a basis for termination under the provision so indicated, and will specify the termination date (which will
be not more than thirty (30) days after the giving of such notice), subject to any applicable cure period. The failure by Executive
or the Company to include in the notice any fact or circumstance which contributes to a showing of Good Reason or Cause, as applicable,
will not waive any right of Executive or the Company, as applicable, hereunder or preclude Executive or the Company, as applicable,
from asserting such fact or circumstance in enforcing Executive’s or its rights hereunder, as applicable.

 

    	-12-

    	

    

 

11.  Miscellaneous Provisions.

 

(a) 
No Duty to Mitigate. Executive will not be required to mitigate the amount of any payment contemplated by this Agreement,
nor will any such payment be reduced by any earnings that Executive may receive from any other source.

 

(b) 
Modifications and Waivers. No provision of this Agreement shall be modified, waived or discharged unless the modification,
waiver or discharge is agreed to in writing and signed by Executive and by an authorized officer of the Company (other than Executive).
No waiver by either party of any breach of, or of compliance with, any condition or provision of this Agreement by the other party
shall be considered a waiver of any other condition or provision or of the same condition or provision at another time.

 

(c) 
Whole Agreement. This Agreement constitutes the entire agreement of the parties hereto and supersedes in their entirety
all prior or contemporaneous representations, understandings, undertakings or agreements (whether oral or written and whether expressed
or implied) of the parties with respect to the subject matter hereof, including, without limitation, any severance provisions contained
in the Employment Agreement. Executive acknowledges and agrees that this Agreement encompasses all the rights of Executive to any
severance payments and/or benefits based on the termination of Executive’s employment and Executive hereby agrees that he
or she has no such rights except as stated herein. No waiver, alteration, or modification of any of the provisions of this Agreement
will be binding unless in writing and signed by duly authorized representatives of the parties hereto and which specifically mention
this Agreement.

 

(d) 
Withholding Taxes. All payments made under this Agreement shall be subject to reduction to reflect taxes or other
deductions required to be withheld by law.

 

(e) 
Choice of Law and Severability. This Agreement shall be interpreted in accordance with the laws of the Commonwealth
of Virginia, without giving effect to provisions governing the choice of law. If any provision of this Agreement becomes or is
deemed invalid, illegal or unenforceable in any applicable jurisdiction by reason of the scope, extent or duration of its coverage,
then such provision shall be deemed amended to the minimum extent necessary to conform to applicable law so as to be valid and
enforceable or, if such provision cannot be so amended without materially altering the intention of the parties, then such provision
shall be stricken and the remainder of this Agreement shall continue in full force and effect. If any provision of this Agreement
is rendered illegal by any present or future statute, law, ordinance or regulation (collectively, the “Law”)
then that provision shall be curtailed or limited only to the minimum extent necessary to bring the provision into compliance with
the Law. All the other terms and provisions of this Agreement shall continue in full force and effect without impairment or limitation.

 

(f)  
No Assignment. This Agreement and all of Executive’s rights and obligations hereunder are personal to Executive
and may not be transferred or assigned by Executive at any time. The Company may assign its rights under this Agreement to any
entity that assumes the Company’s obligations hereunder in connection with any sale or transfer to such entity of all or
a substantial portion of the Company’s assets.

 

    	-13-

    	

    

 

(g) 
Acknowledgment. Executive acknowledges that Executive has had the opportunity to discuss this matter with and obtain
advice from Executive’s personal attorney, has had sufficient time to, and has carefully read and fully understood all the
provisions of this Agreement, and is knowingly and voluntarily entering into this Agreement.

 

(h) 
Counterparts. This Agreement may be executed in two or more counterparts, each of which shall be deemed an original,
but all of which together shall constitute one and the same instrument. Execution of a facsimile or electronic copy will have the
same force and effect as execution of an original, and a facsimile or electronic signature will be deemed an original and valid
signature.

 

(i) 
Electronic Delivery. The Company may, in its sole discretion, decide to deliver any documents related to this Agreement
by electronic means. Executive hereby consents to receive such documents by electronic delivery.

 

[Signature Page
Follows]

 

    	-14-

    	

    

 

IN WITNESS WHEREOF, each of the parties
has executed this Agreement, in the case of the Company by its duly authorized officer, as of the day and year set forth below.

 

	COMPANY	SOC TELEMED, INC.
	 	 
	 	By:	 
	 	 	 
	 	Name:	 
	 	 	 
	 	Title:	 
	 	 	 
	 	Date:	 
	 	 	 
	EXECUTIVE	[EXECUTIVE NAME]
	 	 
	 	By:	 
	 	 	 
	 	Date:	 

 

Attachment A:Form of Separation
Agreement and Release of Claims

 

[Signature Page to Severance and Change in Control Agreement]NEUROPATHIX,
INC.

COMMON
STOCK PURCHASE AGREEMENT

This
Common Stock Purchase Agreement (this “Agreement”), dated as of February 17, 2021, but for all purposes shall
be effective as of February 10, 2021 (the “Effective Date”), is entered into by and between Neuropathix, Inc.,
a Delaware corporation (the “Company”), and Lyons
Capital LLC (the “Investor”). 

RECITALS

A. 
The Company desires to sell 3,500,000 shares of common stock of the Company (the “Common Stock”) to the Investor.

B. 
The Investor desires to purchase 3,500,000 shares of Common Stock from the Company, subject to the terms and conditions set forth
in this Agreement.

NOW
THEREFORE, for good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, the parties hereto
agree as follows:

SECTION
1

PURCHASE AND SALE OF COMMON STOCK

1.1 
Common Stock. Subject to the terms and conditions of this Agreement, the Company shall issue and sell to the Investor,
and the Investor shall purchase from the Company, at the purchase price of $0.10 per share (the “Per Share Price”),
a total of 3,500,000 shares of Common Stock of the Company (the “Shares”).

1.2 
Closing. The purchase and sale of the Shares hereunder shall take place at the Company’s office located at 3805
Old Easton Road, Doylestown, PA 18902 at 10:00 a.m. (EST) on February 10, 2021 (the “Closing”) or at such other
place and time as the Company and the Investor mutually agree. (The date of the Closing is hereinafter referred to as the “Closing
Date.”)

1.3 
Delivery. At the Closing, the Company will deliver to Investor a certificate representing the Shares against delivery
to the Company by Investor at the Closing of (a) an executed counterpart of this Agreement, and (b) the purchase price of
the Shares by wire transfer, a certified or cashier’s check payable to the Company, or by cancellation of indebtedness.

SECTION
2 

REPRESENTATIONS
AND WARRANTIES OF THE COMPANY

The
Company hereby represents and warrants to the Investor that the following representations are true and complete in all material
respects as of the Closing Date.

2.1 
Organization and Standing. The Company is a corporation duly organized and validly existing under the laws of the State
of Delaware and is in good standing under such laws. The Company has the requisite corporate power to own and operate its properties
and assets, and to carry on its business as presently conducted and as proposed to be conducted.

2.2 
Corporate Power. The Company will have at the Closing Date all requisite legal and corporate power to execute and deliver
this Agreement and to sell and issue the Shares hereunder, and to carry out and perform its obligations under the terms of this
Agreement. 

2.3 
Validity. When executed and delivered by the Investor, this Agreement shall be a valid and binding obligation of the
Company enforceable in accordance with its terms, subject to laws of general application relating to bankruptcy, insolvency and
the relief of debtors.

2.4 
Valid Issuance of Stock. The Shares, when issued and paid for as provided in this Agreement,
will be duly authorized and validly issued, fully paid and nonassessable. 

2.5 
Governmental Consents. No consent, approval or authorization of or designation, declaration or filing with any governmental
authority on the part of the Company is required in connection with the valid execution and delivery of this Agreement, or the
offer, sale or issuance of the Shares or the consummation of any other transaction contemplated hereby or thereby, except qualification
(or taking such action as may be necessary to secure an exemption from qualification, if available) of the offer and sale of the
Shares under applicable corporate securities law and other applicable Blue Sky laws, which filing and qualification, if required,
will be accomplished. 

2.6 
Title to Property and Assets. The properties and assets the Company owns are owned by the Company free and clear of
all mortgages, deeds of trust, liens, encumbrances and security interests except for statutory liens for the payment of current
taxes that are not yet delinquent and liens, encumbrances and security interests which arise in the ordinary course of business
and which do not affect material properties and assets of the Company. 

2.7 
Litigation. There is no action, suit, proceeding, claim, arbitration or investigation
(“Action”) pending (or, to the Company’s knowledge, currently threatened)
against the Company, its properties or assets. 

 

2.8

SECTION
3 

REPRESENTATIONS
AND WARRANTIES OF THE INVESTOR

Investor
represents and warrants to the Company that the following representations are true and complete in all material respects as of
the Closing Date:

3.1 
Authorization. This Agreement constitutes the Investor’s valid and legally binding
obligation, enforceable in accordance with its terms except as may be limited by (i) applicable bankruptcy, insolvency, reorganization
or other laws of general application relating to or affecting the enforcement of creditors’ rights generally, and (ii) the
effect of rules of law governing the availability of equitable remedies. Investor represents that Investor has full power and
authority to enter into this Agreement.

3.2 
Validity. When executed and delivered by the Investor, and assuming execution and delivery
by the Company, this Agreement shall constitute a valid obligation of the Investor, enforceable in accordance with its terms.

3.3 
Domicile. The Investor is a resident in the jurisdiction as set forth on the Signature
Page hereto. 

3.4 
Investment Representations. As an inducement to the Company to issue the Shares to Investor,
and in order to establish the suitability for Investor of such an investment, Investor hereby makes the following representations
and warranties, and authorizes the Company to rely upon the same:

(a) 
Investment Intent. Investor is aware of and familiar with the Company’s business affairs and financial condition
and has acquired sufficient information about the Company to reach a knowledgeable and informed decision to acquire the Shares.
Investor is acquiring the Shares for investment for Investor’s own account, not for resale, without any intention of or
view toward or for participating, directly or indirectly, in a distribution of the Shares or any portion thereof.

(b) 
Accredited Investor. The Investor presently qualifies and shall as of the Closing qualify as an “accredited investor”
within the meaning of Regulation D of the rules and regulations promulgated under the Securities Act.

(c) 
Representatives. Investor has consulted with such professional advisors (the “Representatives”),
if any, as Investor has seen fit in connection with this proposed investment.

(d) 
Experience. Investor and Investor’s Representatives, if any, have such knowledge and experience in financial
and business matters that Investor is capable of evaluating the merits and risks of Investor’s investment in the Shares.

(e) 
Risks. Investor understands that an investment in the Company is speculative, that any possible profits therefrom are
uncertain, and that Investor must bear the economic risks of the investment in the Company for an indefinite period of time. Investor
is able to bear these economic risks and to hold the Shares for an indefinite period.

(f) 
Information. Investor and Investor’s Representatives, if any, have received all information and data with respect
to the Company which Investor or Investor’s Representatives have requested and have deemed relevant in connection with an
evaluation of the merits and risks of this investment in the Company, and do not desire any further information or data with respect
to the Company prior to the purchase of the Shares.

(g) 
Securities Laws. Investor understands that (i) the Shares have not been registered under the Securities Act of 1933,
as amended (the “Securities Act”) by reason of a specific exemption therefrom, that the Shares must be held
by Investor indefinitely, and that Investor must, therefore, bear the economic risk of such investment indefinitely, unless a
subsequent disposition thereof is registered under the Securities Act or is exempt from such registration. Investor further understands
that the Shares have not been registered under the “blue sky” laws of any state.

(h) 
Transfers. Investor understands that the Shares may have to be held indefinitely unless they are subsequently registered
under the Securities Act and qualified or registered under other applicable securities laws, rules and regulations, which is highly
unlikely, or unless an exemption from such qualification or registration is available.

(i) 
Legends. Investor understand and agrees that (i) the legends set forth in Section 6 will be placed on the certificate(s)
evidencing the Shares; (ii) the stock records of the Company will be noted with respect to such restrictions; and (iii) the Company
will not be under any obligation to register the Shares or to comply with any exemption available for sale of the Shares without
registration.

(j) 
Further Limitations on Disposition. Investor covenants that in no event shall it dispose of any of the Shares (other
than pursuant to Rule 144 promulgated by under the Securities Act (“Rule 144”) or any similar or analogous
rule) unless and until (a) the Investor shall have notified the Company of the proposed disposition and shall have furnished the
Company with a statement of the circumstances surrounding the proposed disposition, and (b) if requested by the Company, the Investor
shall have furnished the Company with an opinion of counsel satisfactory in form and substance to the Company and the Company’s
counsel to the effect that (x) such disposition shall not require registration under the Securities Act and (y) appropriate action
necessary for compliance with the Securities Act and any applicable state, local, or foreign law has been taken. Notwithstanding
the limitations set forth in the foregoing sentence, if the Investor is a partnership it may transfer Shares to its constituent
partners or a retired partner of such partnership who retires after the date hereof, or to the estate of any such partner or retired
partner or transfer by gift, will, or intestate succession to any such partner’s spouse or lineal descendants or ancestors
without the necessity of registration or opinion of counsel if the transferee agrees in writing to be subject to the terms of
this Agreement to the same extent if such transferee were the Investor; provided, however, that Investor hereby covenants not
to effect such transfer if such transfer either would invalidate the securities laws exemptions pursuant to which the Shares were
originally offered and sold or would itself require registration and/or qualification under the Securities Act or applicable state
securities laws.

(k) 
Valuation of Shares. Investor understands that the Shares have been valued by the Board of Directors of the Company
and that the Company believes this valuation represents a fair attempt at reaching an accurate appraisal of their worth. Investor
understands, however, that the Company can give no assurances that the Price Per Share is in fact the fair market value of the
Shares and that it is possible that the Internal Revenue Service could successfully assert that the value of the Shares on the
date of purchase is greater than so determined.

(l) 
No Tax Advice. Investor understands that Investor may suffer adverse tax consequences as a result of Investor’s
purchase or disposition of the Shares. Investor represents that Investor has consulted any tax consultants Investor deems advisable
in connection with the purchase or disposition of the Shares and that Investor is not relying on the Company or the Company’s
counsel for any tax advice.

3.5 
Survival. The representations and warranties of Investor made pursuant to Section 3 hereof shall survive the Closing.

SECTION
4 

CONDITIONS
TO INVESTOR’S OBLIGATIONS AT CLOSING

The
obligations of Investor under Section 1 of this Agreement are subject to the fulfillment at or before the Closing of each of the
following conditions, any of which may be waived in writing by Investor:

4.1 
Representations and Warranties True. The representations and warranties made by the Company in Section 2 hereof shall
be true and correct in all material respects on the Closing Date with the same force and effect as if they had been made on and
as of said date.

4.2 
Performance of Obligations. The Company shall have performed and complied with all agreements and conditions herein
required to be performed or complied with by it on or before the Closing.

SECTION
5 

CONDITIONS
TO COMPANY’S OBLIGATIONS AT CLOSING

The
Company’s obligation to sell and issue the Shares at the Closing is, at the option of the Company, subject to the fulfillment
on or prior to the Closing of the following conditions:

5.1 
Representations and Warranties True. The representations and warranties made by the Investor in Section 3 hereof shall
be true and correct in all material respects on the Closing Date with the same force and effect as if they had been made on and
as of said date.

5.2 
Performance of Obligations. The Investor shall have performed and complied with all agreements and conditions herein
required to be performed or complied with by Investor on or before the Closing.

5.3 
Legal Matters. All material matters of a legal nature which pertain to this Agreement and the transactions contemplated
hereby shall have been reasonably approved by counsel for the Company. 

SECTION
6 

RESTRICTIVE
LEGENDS AND STOP-TRANSFER ORDERS

6.1 
Restrictive Legends.

(a) 
Federal Legends. All certificates evidencing the Shares shall bear such restrictive legends as the Company and the
Company’s counsel deem necessary or advisable under applicable law or pursuant to this Agreement, including, without limitation,
the following:

 

 

 

“THE
SECURITIES EVIDENCED BY THIS CERTIFICATE HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED, AND MAY NOT BE
SOLD, TRANSFERRED, ASSIGNED OR HYPOTHECATED UNLESS THERE IS AN EFFECTIVE REGISTRATION STATEMENT UNDER SUCH ACT COVERING SUCH SECURITIES,
THE SALE IS MADE IN ACCORDANCE WITH RULE 144 UNDER THE ACT, OR THE COMPANY RECEIVES AN OPINION OF COUNSEL FOR THE HOLDER
OF THESE SECURITIES REASONABLY SATISFACTORY TO THE COMPANY STATING THAT SUCH SALE, TRANSFER, ASSIGNMENT OR HYPOTHECATION IS EXEMPT
FROM THE REGISTRATION AND PROSPECTUS DELIVERY REQUIREMENTS OF SUCH ACT.”

(b) 
Other Legends. The certificates evidencing the Shares shall also bear any legend required by law of the State of Pennsylvania
or required pursuant to any state, local, or foreign law governing such securities.

6.2 
Stop-Transfer Notices. Investor agrees that, in order to ensure compliance with the restrictions
referred to herein, the Company may issue appropriate “stop transfer” instructions to its transfer agent, if any,
and that, if the Company transfers its own securities, it may make appropriate notations to the same effect in its own records.

6.3 
Refusal to Transfer. The Company shall not be required (i) to transfer on its books
any Shares that have been sold or otherwise transferred in violation of any of the provisions of this Agreement, or (ii) to
treat as owner of such Shares or to accord the right to vote or pay dividends to any purchaser or other transferee to whom such
Shares shall have been so transferred.

6.4 
Removal of Legend and Transfer Restrictions. Any legend endorsed on a certificate pursuant to Sections 6.1(a)
and (b) and the stop transfer instructions with respect to such legended securities shall be removed, and the Company shall
issue a certificate without such legend to the holder of such securities, if such securities are registered under the Securities
Act and a prospectus meeting the requirements of Section 10 of the Securities Act is available with respect to such Shares
or if such holder satisfies the requirements of Rule 144.

SECTION
7 

MISCELLANEOUS

7.1 
Piggyback Registration Rights. Whenever the Company proposes to register any of its securities
under the Securities Act, as amended (other than pursuant to a registration primarily for sales of securities to employees of
the Company under Form S-8 or pursuant to a business combination under Form S-4), the Company will include in such registration
the Shares sold to Investor under this Agreement. 

7.2 
Governing Law; Venue. This Agreement shall be governed by and construed in accordance with the laws of the State of
Pennsylvania, without reference to principles of conflicts of laws or choice of laws. The prevailing party in any action to enforce
this Agreement shall be entitled to costs and fees (including attorneys’ fees and expert witness fees) incurred in connection
with such action. Each party agrees that service of process on them in any such action, suit or proceeding may be effected by
the means by which notices are to be given to it under this Agreement. The parties hereby irrevocably submit to the jurisdiction
of the State and Federal courts located in Bucks County, State of Pennsylvania (which courts, for purposes of this Agreement,
are the only courts of competent jurisdiction), over any suit, action or other proceeding arising out of, under, or in connection
with this Agreement or its subject matter.

7.3 
Successors and Assigns. Except as otherwise expressly provided herein, the provisions hereof shall inure to the benefit
of, and be binding upon, the successors, assigns, heirs, executors and administrators of the parties hereto; provided, however,
that the rights of Investor to purchase the Shares shall not be assignable without the written consent of the Company.

7.4 
Entire Agreement. This Agreement constitutes the entire agreement of the parties with regard to the subject matter
hereof and supersedes any and all prior negotiations, correspondence, understandings and agreements among the parties regarding
the subject matter hereof, whether oral or written.

7.5 
Notices, Etc. All notices and other communications required or permitted hereunder shall be in writing and shall be
deemed effectively given (i) upon actual delivery to the party to be notified, (ii) three (3) business days after having
been sent by registered or certified mail, return receipt requested, postage prepaid, or (iii) one business day after deposit
with a recognized overnight courier, specifying next business day delivery, addressed (a) if to Investor, at the address
set forth beneath Investor’s signature hereto, or at such other address as the Investor shall have furnished to the Company
in writing upon 10 days’ notice; (b) if to any other holder of any Shares, at such address as such holder shall have
furnished the Company in writing upon 10 days’ notice or, until any such holder so furnishes an address to the Company,
to and at the address of the last holder of such Shares who has so furnished an address to the Company; or (c) if to the
Company, at the following address or at such other address as the Company shall have furnished to the Investor upon 10 days’
notice:

Neuropathix,
Inc.

3805
Old Easton Road

Doylestown,
PA 18902

Attention:
Chief Executive Officer

 

With
a copy to (which shall not constitute notice):

Procopio,
Cory, Hargreaves & Savitch LLP

12544
High Bluff Drive, Suite 400

San
Diego, CA 92130

Attention:
Christopher Tinen, Esq.

7.6 
Expenses and Fees. Each party shall pay its own expenses incurred, including any legal fees or costs, in connection
with the transactions described in this Agreement.

7.7 
Severability. In case any one or more of the provisions contained in this Agreement shall, for any reason, be judicially
determined to be invalid, illegal or unenforceable in any respect, (i) the remaining terms and provisions hereof shall be unimpaired
and shall remain in full force and effect, and (ii) the invalid or unenforceable provision or term shall be replaced by a term
or provision that is valid and enforceable and that comes closest to expressing the intention of such invalid or unenforceable
term or provision, and, if the foregoing provision of this clause (ii) is not permitted pursuant to applicable law, then (iii)
this Agreement shall be construed as if such invalid, illegal or unenforceable provision had never been contained herein.

7.8 
Delays or Omissions. It is agreed that no delay or omission to exercise any right, power or remedy accruing to any
party, upon any breach, default or noncompliance by any other party under this Agreement, shall impair any such right, power or
remedy, nor shall it be construed to be a waiver of any such breach, default or noncompliance, or any acquiescence therein, or
of any similar breach, default or noncompliance thereafter occurring. It is further agreed that any waiver, permit, consent or
approval of any kind or character on the part of any party of any breach, default or noncompliance under the Agreement, or any
waiver on the part of any party of any provisions or conditions of this Agreement, must be in writing and shall be effective only
to the extent specifically set forth in such writing. All remedies, either under this Agreement, by law, or otherwise afforded
to any party, shall be cumulative and not alternative.

7.9 
Approval of Amendments and Waivers. Any term of this Agreement may be amended and the observance of any term of this
Agreement may be waived (either generally or in a particular instance and either retroactively or prospectively) only with the
written consent of, or a written instrument signed by (i) the Company, and (ii) Investor.

7.10 
Titles and Subtitles; References. The titles and subtitles used in this Agreement are used for convenience only and
are not to be considered in construing or interpreting this Agreement. All references in this Agreement to sections, paragraphs,
exhibits and schedules shall, unless otherwise provided, refer to sections and paragraphs hereof and exhibits and schedules attached
hereto, all of which exhibits and schedules are incorporated herein by this reference.

7.11 
Construction. The Company and the Investor have participated jointly in the negotiation
and drafting of this Agreement. 

7.12 
Further Assurances. Each of the parties to this Agreement shall execute and deliver all additional documents and instruments
and shall do all acts and things reasonably requested (a) in connection with the performance of the obligations undertaken in
this Agreement; (b) to evidence the transactions contemplated by this Agreement; and (c) otherwise to effectuate in good faith
the intent of the parties.

7.13 
Telecopy Execution and Delivery. A facsimile, telecopy or other reproduction of this Agreement may be executed by one
or more parties hereto and delivered by such party by facsimile or any similar electronic transmission device pursuant to which
the signature of or on behalf of such party can be seen. Such execution and delivery shall be considered valid, binding and effective
for all purposes. At the request of any party hereto, all parties hereto agree to execute and deliver an original of this Agreement
as well as any facsimile, telecopy or other reproduction hereof.

7.14 
Counterparts. This Agreement may be executed in any number of counterparts, each of which when so executed and delivered
will be deemed an original, and all such counterparts together will constitute one and the same instrument.

 

[Signature
Page Follows]

    	 	1	 

     

    

 

IN
WITNESS WHEREOF, the parties hereto have executed this Agreement as of the date set forth in the first paragraph hereof.

	COMPANY:

        NEUROPATHIX,
        INC.

        

        _______________________________

        Dean Petkanas, its CEO

         

         
	INVESTOR:

        LYONS
        CAPITAL LLC

        

        _______________________________

        Jason Lyons, its Chairman

         

        Address:

        _______________________________

        _______________________________

        _______________________________

        Telephone:
        _____________________

        Facsimile:
        _____________________

        Email:
        ________________________

         

         

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

[Signature
Page to Common Stock Purchase Agreement.]

    	 	2

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00321-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00321-of-00352.parquet"}]]